DeepLife utilizes deep learning algorithms on multi-omics data to create digital twins of cells, enabling precise modeling and engineering of cellular behavior. This technology enhances drug discovery by providing accurate simulations of cellular responses, reducing the time and cost associated with traditional experimental methods.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CDEFFounders
Product
Problem
Traditional drug discovery methods are time-consuming and expensive, often relying on experimental techniques that lack precise modeling of cellular behavior. The complexity of cellular responses to drug candidates makes it difficult to predict efficacy and toxicity early in the development process.
Solution
DeepLife offers a platform that constructs digital twins of cells using deep learning algorithms applied to multi-omics data. This technology enables accurate simulation and prediction of cellular responses to drug candidates, facilitating more efficient and targeted drug discovery. By creating detailed, data-driven models of cellular behavior, DeepLife reduces the reliance on traditional experimental methods, accelerating the identification of promising drug candidates and minimizing the risk of late-stage failures. The platform allows researchers to explore cellular dynamics and optimize drug design through in silico experiments.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and academic research institutions involved in drug discovery and development.
Features
- Deep learning models trained on multi-omics data to create digital twins of cells
- Simulation capabilities for predicting cellular responses to drug candidates
- In silico experimentation to optimize drug design and identify potential targets
- Data exploration tools for analyzing cellular behavior and identifying key biomarkers